Influenza vaccination and use of lipid lowering therapies in adults with atherosclerotic cardiovascular disease: An analysis of the Behavioral Risk Factor Surveillance System (BRFSS)
Authors' conclusion
Unvaccinated status for influenza was independently associated with 34% lower odds of LLT use among American adults with ASCVD after adjustment for traditional factors linked to underuse of preventive therapies.
Study context
- Population
- US adults aged 40 to 75 years with self-reported atherosclerotic cardiovascular disease (ASCVD) (BRFSS)
- Participants
- 66,923 adults
- Exposure
- Unvaccinated vs vaccinated for influenza
- Outcome
- Self-reported LLT use
Methodological detailspooled 2017, 2019 and 2021 BRFSS survey data, complex survey weighting, multiple imputation sensitivity analysis
- Pooled 2017, 2019 and 2021 BRFSS survey data
- Complex survey weighting
- Multiple imputation sensitivity analysis
Main finding
As reported in the abstract
LLT use
Unvaccinated vs VaccinatedEstimate (95% CI)P value
Unadjusted
OR 0.54(0.50–0.58)
P < 0.001Adjusted for demographics and comorbidities
aOR 0.58(0.52–0.64)
P < 0.001Observational data: associations, not effects.
Further findings
Lipid lowering therapy (LLT) use, by subgroup (incl. with and without hyperlipidemia)
- No significant differences across subgroups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Influenza vaccination and use of lipid lowering therapies in adults with atherosclerotic cardiovascular disease: An analysis of the Behavioral Risk Factor Surveillance System (BRFSS). Am Heart J. Published 11 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →